Del. Teresa Reilly

Maddy summaryHB 996, the Phenibut Consumer Protection Act, regulates the sale of phenibut products (containing beta-phenyl-gamma-aminobutyric acid HCL) by requiring retailers to disclose factual claims on product labels and prohibiting sales of unsafe or mislabeled products. It bans selling phenibut to anyone under 21, prohibits advertising therapeutic benefits or marketing to minors (including restrictions on cartoons, superheroes, or youth-targeted imagery), and bans products adulterated with dangerous substances. Retailers violating these rules face civil penalties up to $1,000 for labeling issues or criminal fines up to $5,000 for safety or age violations. The bill also mandates the Maryland Department of Health to report on adverse health events linked to phenibut use by the legislature.

Maddy summaryHB 1478 requires the Maryland Department of Health to create and maintain an online directory of home health care providers. The directory must let people search for providers by criteria like language skills, certifications, or special training, and include details such as provider names, licenses, training, and abuse reports. It directly affects individuals seeking home health care services (like nursing or therapy in their homes) and the home health care providers themselves. The bill does not change licensing rules but aims to make it easier for people to find qualified providers and supports provider recruitment through features like job listings and training connections.

Maddy summaryHB 936 requires health insurance carriers to provide written notice of cancellation or nonrenewal for small group health plans to affected small employers and employees at least 90 days in advance. Notices must be sent via certified mail (return receipt requested) and electronically, including information about alternative coverage options like COBRA or plans through the Maryland Health Benefit Exchange. The bill applies specifically to small group market plans and takes effect July 1, 2025. It mandates carriers to offer affected employers other available plans and prohibits discrimination based on health status.

Maddy summaryHB 1243 prohibits health insurers, nonprofit health plans, and health maintenance organizations (HMOs) in Maryland from excluding coverage for certain specialty drugs administered or dispensed by in-network oncology providers meeting state regulations. The bill defines "specialty drugs" as those costing $600+ for a 30-day supply, treating complex/chronic conditions (excluding diabetes/HIV/AIDS), and requiring special handling or patient support. It requires insurers to reimburse these drugs at non-hospital rates and covers infused, auto-injected, or specific oral medications used with other therapies. This directly affects patients needing these drugs and providers administering them, ensuring coverage access without insurer-imposed pharmacy restrictions.

Maddy summaryHB 970 prohibits Maryland health insurers, nonprofit health plans, and health maintenance organizations from requiring patients to try less expensive diabetes medications before covering insulin. It directly affects people with type 1, type 2, or gestational diabetes who rely on insulin or similar insulin analogs for treatment. The bill bans "step therapy" or "fail-first" protocols - where insurers force patients to attempt alternative drugs first - regardless of how insurers label these policies. This change takes effect for all new or renewed health insurance policies on or after January 1, 2026.

Maddy summaryHB 1355 requires health insurers in Maryland to cover medically necessary hearing aids for adults if the devices are ordered, fitted, and dispensed by a licensed hearing aid dispenser (in addition to coverage when prescribed by an audiologist). Insurers must cover up to $1,400 per hearing aid per ear every three years, but enrollees can choose more expensive devices and pay the difference without penalty. The law applies to all health insurance policies issued, delivered, or renewed in Maryland on or after January 1, 2026. This directly affects adults with hearing loss covered by health insurance plans subject to Maryland’s insurance regulations.

Maddy summaryHB 798 requires Maryland's Office of Overdose Response (with the Department of Health) to create and maintain a public interactive dashboard tracking how settlement funds from opioid-related lawsuits are spent. The dashboard must show, by state, county, and municipality: payment schedules, past spending, spending plans, funded initiatives, and public hearing details. Local governments receiving these funds must submit required financial data through an online portal to the Department for inclusion on the dashboard. The dashboard will be developed and maintained using existing Opioid Restitution Fund money from the state budget, not new appropriations. This bill focuses solely on transparency, with no new policy changes or funding mechanisms.

Maddy summaryHB 1146 requires Maryland's crisis communication centers to coordinate with the 9-8-8 Suicide and Crisis Lifeline Network to provide services like supportive counseling, suicide prevention, crisis intervention, and referrals. It mandates that each jurisdiction's crisis system evaluate outcomes using specific data points, including 9-8-8 call volume, resolution rates, mobile crisis team dispatches, and discharge data. The bill also requires annual public reporting of this data - disaggregated by race, gender, age, and zip code - to inform policy improvements aimed at reducing criminal detention and enhancing community crisis diversion. This directly affects all Maryland crisis communication centers and their coordination with the 9-8-8 network.

Maddy summaryHB 1004 requires the Maryland Department of Health to incorporate FDA-approved Alzheimer's treatments into public health outreach programs for healthcare providers and the public. It mandates the department to create a publicly accessible website displaying statewide prevalence and hospitalization rates for Alzheimer's and related dementias, disaggregated by age, race, ethnicity, sex, and county. The bill specifically targets improving early detection awareness, emphasizing Medicare wellness visits for seniors, and addressing higher risk in Black and Latino communities. The website must include data from the previous five years and be updated annually starting in 2027.

Maddy summaryHB 1087 prohibits Maryland health insurers, nonprofit health plans, and health maintenance organizations from requiring step therapy (where patients must try less expensive drugs first) for two specific cancer-related treatments. It applies when: (1) a drug treats stage 4 metastatic cancer itself (if FDA-approved and supported by medical evidence), or (2) a drug treats a symptom or side effect from cancer treatment (if determined necessary by a provider and backed by medical literature). The law affects patients with advanced metastatic cancer who rely on these specific prescription drugs and requires insurers to cover them without prior authorization hurdles. The bill amends Maryland insurance law and takes effect January 1, 2026.